Uric acid preconditioning alleviated doxorubicin induced JNK activation and Cx43 phosphorylation associated cardiotoxicity via activation of AMPK-SHP2 signaling pathway

Jiawei Wang,Yixin Fan,Xiaomin Cai,Zhenzhen Gao,Zhengyi Yu,Bin Wei,Yulin Tang,Liang Hu,Wen-Tao Liu,Yanhong Gu
DOI: https://doi.org/10.21037/atm-20-3105
IF: 3.616
2020-12-01
Annals of Translational Medicine
Abstract:BACKGROUND: Doxorubicin is an anthracycline antibiotic, which is effective for treating various malignancies such as leukemias and lymphomas. However, its serious cumulative dose-dependent cardiotoxicity limits its clinical application. Previous studies have shown that doxorubicin-associated cardiotoxicity is closely related to adenosine 5'-monophosphate (AMP)-activated protein kinase (AMPK). Uric acid is known to exert a strong antioxidant function and moderate protection on the nerves. However, its cardioprotective properties have not been established. This study aimed to investigate the potential effect of uric acid preconditioning on doxorubicin-induced cardiotoxicity and the involvement of AMPK signaling in this process.METHODS: An acute cardiotoxicity model of doxorubicin was established by intraperitoneal injection of a single dose of doxorubicin (20 mg/kg) in mice. Uric acid (62.5, 125, and 250 mg/kg) was intragastrically administered to mice one day before doxorubicin treatment and then continuously administered every 24 h for 8 consecutive days. The mortality rate and weight of the mice were recorded every day. Electrocardiograms (ECG) and serum biochemicals were detected with an ECG instrument and enzyme-linked immunosorbent assay kit (Elisa) respectively. A real-time cell analyzer (RTCA) was used to investigate the cytotoxicity of doxorubicin <i>in vitro</i>. Cell signaling was assayed by western blotting.RESULTS: Uric acid (125 mg/kg) preconditioning increased the survival rate and body weight of doxorubicin-treated mice. Uric acid also effectively alleviated prolongation of the doxorubicin-induced QT interval, slowed heart rate, and reduced the plasma levels of aspartate aminotransferase (AST), lactate dehydrogenase (LDH) and creatine kinase (CK) in plasma in mice. Moreover, uric acid strongly activated AMPK and Src homology 2 domain-containing protein tyrosine phosphatase (SHP2), inhibiting doxorubicin-induced expression phosphorylated-c-Jun N-terminal kinases (JNK) and phosphorylated-connexin 43 (Cx43) <i>in vitro</i> and <i>in vivo</i> and effectively reversing the doxorubicin-induced decreased viability of H9C2 myocardial cells <i>in vitro</i>.CONCLUSIONS: We demonstrated that uric acid preconditioning alleviated doxorubicin-induced cardiotoxicity through the AMPK-SHP2-JNK-Cx43 signaling pathway.
oncology,medicine, research & experimental
What problem does this paper attempt to address?
The main problem that this paper attempts to solve is the cumulative dose - dependent cardiotoxicity caused by doxorubicin (a widely - used chemotherapeutic drug), which limits its clinical application. Specifically, the study aims to explore the potential impact of uric acid pretreatment on doxorubicin - induced cardiotoxicity and the role of the AMPK signaling pathway in this process. By establishing a mouse model of acute doxorubicin cardiotoxicity, the paper studied whether different concentrations of uric acid pretreatment could reduce the cardiotoxicity caused by doxorubicin and further explored the mechanism by which uric acid pretreatment inhibits JNK and Cx43 phosphorylation by activating the AMPK - SHP2 signaling pathway, thereby reducing cardiotoxicity. The research results show that uric acid pretreatment can significantly improve the survival rate and body weight of mice treated with doxorubicin, effectively relieve the QT interval prolongation, bradycardia, and the increase in the levels of aspartate aminotransferase (AST), lactate dehydrogenase (LDH), and creatine kinase (CK) in plasma caused by doxorubicin. In addition, uric acid pretreatment also strongly activates AMPK and Src homology 2 domain - containing protein tyrosine phosphatase (SHP2), inhibits the phosphorylation of JNK and Cx43 induced by doxorubicin, and thus effectively reverses the decrease in the viability of H9C2 cardiomyocytes caused by doxorubicin. In conclusion, this study reveals a new mechanism by which uric acid pretreatment reduces doxorubicin - induced cardiotoxicity through the AMPK - SHP2 - JNK - Cx43 signaling pathway, providing a theoretical basis for the development of new prevention or treatment strategies.